Publication & Citation Trends
Most Cited Works
Publications
140 total
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Cited by 1,435
OpenAlex
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) PDF
Cited by 784
OpenAlex
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC PDF
Cited by 499
OpenAlex
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC PDF
Cited by 1,647
OpenAlex
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial PDF
Cited by 594
OpenAlex
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial PDF
Cited by 439
OpenAlex
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition PDF
Cited by 258
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(47)
Cancer Immunotherapy and Biomarkers
(32)
Cancer, Hypoxia, and Metabolism
(23)
Cancer Genomics and Diagnostics
(19)
RNA modifications and cancer
(17)
Frequent Co-Authors
Affiliations
University of North Carolina at Chapel Hill
Children's Hospital of Philadelphia
University of California, San Francisco
Biomarker Technologies (China)
Acentech (United States)